Results

Weight Loss Study: Zepbound Outshines Wegovy in Key Weight Loss Trial

Monday, May 12, 2025, 9:21 am more...

A new head‐to‐head study reveals that Eli Lilly’s obesity drug Zepbound significantly outperformed Novo Nordisk’s Wegovy, with patients losing nearly 50% more weight. The dramatic results have stirred both excitement and a few wry smiles among the medical community as the weight loss war intensifies.

globalnews.ca / Zepbound beats Wegovy rival in 1st head-to-head weight loss study

torontosun.com / Lilly’s Zepbound trims more belly fat than Novo’s Wegovy: Study

permalink / 2 stories from sources in 10 hours ago #business #nutrition #health #fitness +


Loading...
No more content.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.